Log In
BCIQ
Print this Print this
 

veltuzumab-Rap

  Manage Alerts
Collapse Summary General Information
Company Immunomedics Inc.
DescriptionHumanized antibody targeting CD20 fused to an amphibian RNase using dock and lock (DNL) conjugation technology
Molecular Target CD20
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Fusion protein

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today